Editas Medicine (EDIT) Reports In-Line Q1 EPS

Editas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.79), in-line with the analyst estimate of ($0.79). Revenue for the quarter came in at $9.9 million versus the consensus estimate of $3.29 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Dollar Tree upgraded on earnings upside potential despite ongoing traffic woes
• DigitalOcean (DOCN) Reiterated at Overweight by Cantor Fitzgerald on Q2 Pre-Announcement
• Abitibi Metals names new CFO, halts drilling on Quebec fire order